Castle Biosciences Inc
NASDAQ:CSTL
Castle Biosciences Inc
NASDAQ:CSTL
Price:
24.24 USD
0.08%
Market Closed
Updated:
May 19, 2024
Castle Biosciences Inc
Income from Continuing Operations
|
Castle Biosciences Inc
Income from Continuing Operations Peer Comparison
Comparables:
DVA
DGX
CVS
CI
LH
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Castle Biosciences Inc
NASDAQ:CSTL
|
Income from Continuing Operations
-$30.8m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-50%
|
CAGR 10-Years
N/A
|
|
|
DaVita Inc
NYSE:DVA
|
Income from Continuing Operations
$1.1B
|
CAGR 3-Years
2%
|
CAGR 5-Years
9%
|
CAGR 10-Years
2%
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Income from Continuing Operations
$870m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
4%
|
CAGR 10-Years
0%
|
|
|
CVS Health Corp
NYSE:CVS
|
Income from Continuing Operations
$7.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
4%
|
|
|
Cigna Corp
NYSE:CI
|
Income from Continuing Operations
$3.9B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Income from Continuing Operations
$400.3m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-3%
|
See Also
What is Castle Biosciences Inc's Income from Continuing Operations?
Income from Continuing Operations
-30.8m
USD
-30.8m
USD
Based on the financial report for Mar 31, 2024, Castle Biosciences Inc's Income from Continuing Operations amounts to -30.8m USD.
What is Castle Biosciences Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-50%
-50%
Over the last year, the Income from Continuing Operations growth was 57%. The average annual Income from Continuing Operations growth rates for Castle Biosciences Inc have been -27% over the past three years , -50% over the past five years .
You don't have any saved screeners yet
